ID   PRKN_HUMAN              Reviewed;         465 AA.
AC   O60260; A3FG77; A8K975; D3JZW7; D3K2X0; Q5TFV8; Q5VVX4; Q6Q2I6;
AC   Q8NI41; Q8NI43; Q8NI44; Q8WW07;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   13-NOV-2019, entry version 205.
DE   RecName: Full=E3 ubiquitin-protein ligase parkin {ECO:0000305};
DE            Short=Parkin;
DE            EC=2.3.2.31 {ECO:0000269|PubMed:23770887};
DE   AltName: Full=Parkin RBR E3 ubiquitin-protein ligase {ECO:0000312|HGNC:HGNC:8607};
DE   AltName: Full=Parkinson juvenile disease protein 2;
DE            Short=Parkinson disease protein 2;
GN   Name=PRKN {ECO:0000312|HGNC:HGNC:8607}; Synonyms=PARK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND INVOLVEMENT IN
RP   PARK2.
RC   TISSUE=Fetal brain, and Skeletal muscle;
RX   PubMed=9560156; DOI=10.1038/33416;
RA   Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y.,
RA   Minoshima S., Yokochi M., Mizuno Y., Shimizu N.;
RT   "Mutations in the parkin gene cause autosomal recessive juvenile
RT   parkinsonism.";
RL   Nature 392:605-608(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   VARIANTS ARG-311 AND THR-371, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19501131; DOI=10.1016/j.neulet.2009.05.079;
RA   Kasap M., Akpinar G., Sazci A., Idrisoglu H.A., Vahaboglu H.;
RT   "Evidence for the presence of full-length PARK2 mRNA and Parkin
RT   protein in human blood.";
RL   Neurosci. Lett. 460:196-200(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RA   D'Agata V., Scapagnini G., Cavallaro S.;
RT   "Functional and molecular diversity of parkin.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 7 AND 8).
RC   TISSUE=Retina;
RA   Campello L., Esteve-Rudd J., Cuenca N., Martin-Nieto J.;
RT   "Homo sapiens PARK2 transcript variants.";
RL   Submitted (DEC-2009) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 312-361.
RA   Zou H.Q., Chan P.;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10319893;
RX   DOI=10.1002/1531-8249(199905)45:5<668::aid-ana19>3.0.co;2-z;
RA   Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T.,
RA   Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N.,
RA   Mizuno Y.;
RT   "Immunohistochemical and subcellular localization of Parkin protein:
RT   absence of protein in autosomal recessive juvenile parkinsonism
RT   patients.";
RL   Ann. Neurol. 45:668-672(1999).
RN   [11]
RP   FUNCTION IN UBIQUITINATION.
RX   PubMed=10973942; DOI=10.1074/jbc.c000447200;
RA   Imai Y., Soda M., Takahashi R.;
RT   "Parkin suppresses unfolded protein stress-induced cell death through
RT   its E3 ubiquitin-protein ligase activity.";
RL   J. Biol. Chem. 275:35661-35664(2000).
RN   [12]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS PARK2 PRO-42 AND ARG-240.
RX   PubMed=10888878; DOI=10.1038/77060;
RA   Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S.,
RA   Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T.;
RT   "Familial Parkinson disease gene product, parkin, is a ubiquitin-
RT   protein ligase.";
RL   Nat. Genet. 25:302-305(2000).
RN   [13]
RP   INTERACTION WITH UBE2L6 AND SEPTIN5, AND UBIQUITINATION OF SEPTIN5.
RX   PubMed=11078524; DOI=10.1073/pnas.240347797;
RA   Zhang Y., Gao J., Chung K.K.K., Huang H., Dawson V.L., Dawson T.M.;
RT   "Parkin functions as an E2-dependent ubiquitin-protein ligase and
RT   promotes the degradation of the synaptic vesicle-associated protein,
RT   CDCrel-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:13354-13359(2000).
RN   [14]
RP   UBIQUITINATION OF GPR37.
RX   PubMed=11439185; DOI=10.1016/s0092-8674(01)00407-x;
RA   Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R.;
RT   "An unfolded putative transmembrane polypeptide, which can lead to
RT   endoplasmic reticulum stress, is a substrate of Parkin.";
RL   Cell 105:891-902(2001).
RN   [15]
RP   FUNCTION, CHARACTERIZATION OF VARIANTS PARK2 ARG-240; CYS-256; TRP-275
RP   AND ASN-415, AND MUTAGENESIS OF CYS-337; CYS-421 AND CYS-431.
RX   PubMed=11590439; DOI=10.1038/nm1001-1144;
RA   Chung K.K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J.,
RA   Ross C.A., Dawson V.L., Dawson T.M.;
RT   "Parkin ubiquitinates the alpha-synuclein-interacting protein,
RT   synphilin-1: implications for Lewy-body formation in Parkinson
RT   disease.";
RL   Nat. Med. 7:1144-1150(2001).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS PARK2
RP   PRO-42 AND ARG-240.
RX   PubMed=11431533; DOI=10.1126/science.1060627;
RA   Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P.,
RA   Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J.;
RT   "Ubiquitination of a new form of alpha-synuclein by parkin from human
RT   brain: implications for Parkinson's disease.";
RL   Science 293:263-269(2001).
RN   [17]
RP   PRESENCE OF ATYPICAL RING FINGER DOMAINS.
RX   PubMed=12446796; DOI=10.1093/oxfordjournals.molbev.a004029;
RA   Marin I., Ferrus A.;
RT   "Comparative genomics of the RBR family, including the Parkinson's
RT   disease-related gene parkin and the genes of the ariadne subfamily.";
RL   Mol. Biol. Evol. 19:2039-2050(2002).
RN   [18]
RP   INTERACTION WITH STUB1 AND HSP70, AND UBIQUITINATION OF STUB1.
RX   PubMed=12150907; DOI=10.1016/s1097-2765(02)00583-x;
RA   Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.,
RA   Takahashi R.;
RT   "CHIP is associated with Parkin, a gene responsible for familial
RT   Parkinson's disease, and enhances its ubiquitin ligase activity.";
RL   Mol. Cell 10:55-67(2002).
RN   [19]
RP   INTERACTION WITH SYT11, AND CHARACTERIZATION OF VARIANTS PARK2 GLY-289
RP   AND ARG-418.
RX   PubMed=12925569; DOI=10.1093/hmg/ddg269;
RA   Huynh D.P., Scoles D.R., Nguyen D., Pulst S.M.;
RT   "The autosomal recessive juvenile Parkinson disease gene product,
RT   parkin, interacts with and ubiquitinates synaptotagmin XI.";
RL   Hum. Mol. Genet. 12:2587-2597(2003).
RN   [20]
RP   INTERACTION WITH PACRG.
RX   PubMed=14532270; DOI=10.1074/jbc.m309655200;
RA   Imai Y., Soda M., Murakami T., Shoji M., Abe K., Takahashi R.;
RT   "A product of the human gene adjacent to parkin is a component of Lewy
RT   bodies and suppresses Pael receptor-induced cell death.";
RL   J. Biol. Chem. 278:51901-51910(2003).
RN   [21]
RP   FUNCTION, INTERACTION WITH FBXW7 AND CUL1, AND UBIQUITINATION OF
RP   CYCLIN E.
RX   PubMed=12628165; DOI=10.1016/s0896-6273(03)00084-9;
RA   Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E.,
RA   Abeliovich A.;
RT   "Parkin is a component of an SCF-like ubiquitin ligase complex and
RT   protects postmitotic neurons from kainate excitotoxicity.";
RL   Neuron 37:735-749(2003).
RN   [22]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=14614460; DOI=10.1038/sj.onc.1207072;
RA   Denison S.R., Wang F., Becker N.A., Schuele B., Kock N.,
RA   Phillips L.A., Klein C., Smith D.I.;
RT   "Alterations in the common fragile site gene Parkin in ovarian and
RT   other cancers.";
RL   Oncogene 22:8370-8378(2003).
RN   [23]
RP   FUNCTION, AND INVOLVEMENT IN CANCER.
RX   PubMed=12719539; DOI=10.1073/pnas.0931262100;
RA   Cesari R., Martin E.S., Calin G.A., Pentimalli F., Bichi R.,
RA   McAdams H., Trapasso F., Drusco A., Shimizu M., Masciullo V.,
RA   D'Andrilli G., Scambia G., Picchio M.C., Alder H., Godwin A.K.,
RA   Croce C.M.;
RT   "Parkin, a gene implicated in autosomal recessive juvenile
RT   parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-
RT   q27.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5956-5961(2003).
RN   [24]
RP   REVIEW.
RX   PubMed=15229644; DOI=10.1038/sj.embor.7400188;
RA   Kahle P.J., Haass C.;
RT   "How does parkin ligate ubiquitin to Parkinson's disease?";
RL   EMBO Rep. 5:681-685(2004).
RN   [25]
RP   FUNCTION, UBIQUITINATION, AND S-NITROSYLATION.
RX   PubMed=15105460; DOI=10.1126/science.1093891;
RA   Chung K.K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C.,
RA   Marsh L., Dawson V.L., Dawson T.M.;
RT   "S-nitrosylation of parkin regulates ubiquitination and compromises
RT   parkin's protective function.";
RL   Science 304:1328-1331(2004).
RN   [26]
RP   INTERACTION WITH PSMA7.
RX   PubMed=15987638; DOI=10.1016/j.febslet.2005.06.003;
RA   Dachsel J.C., Lucking C.B., Deeg S., Schultz E., Lalowski M.,
RA   Casademunt E., Corti O., Hampe C., Patenge N., Vaupel K., Yamamoto A.,
RA   Dichgans M., Brice A., Wanker E.E., Kahle P.J., Gasser T.;
RT   "Parkin interacts with the proteasome subunit alpha4.";
RL   FEBS Lett. 579:3913-3919(2005).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH SNCAIP.
RX   PubMed=15728840; DOI=10.1523/jneurosci.4474-04.2005;
RA   Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y.,
RA   Tanaka Y., Smith W., Engelender S., Ross C.A., Dawson V.L.,
RA   Dawson T.M.;
RT   "Parkin mediates nonclassical, proteasomal-independent ubiquitination
RT   of synphilin-1: implications for Lewy body formation.";
RL   J. Neurosci. 25:2002-2009(2005).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH AIMP2.
RX   PubMed=16135753; DOI=10.1523/jneurosci.2172-05.2005;
RA   Ko H.S., von Coelln R., Sriram S.R., Kim S.W., Chung K.K.K.,
RA   Pletnikova O., Troncoso J., Johnson B., Saffary R., Goh E.L., Song H.,
RA   Park B.-J., Kim M.J., Kim S., Dawson V.L., Dawson T.M.;
RT   "Accumulation of the authentic parkin substrate aminoacyl-tRNA
RT   synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell
RT   death.";
RL   J. Neurosci. 25:7968-7978(2005).
RN   [29]
RP   INTERACTION WITH LRRK2.
RX   PubMed=16352719; DOI=10.1073/pnas.0508052102;
RA   Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B.,
RA   Dawson V.L., Dawson T.M., Ross C.A.;
RT   "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant
RT   LRRK2 induces neuronal degeneration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18676-18681(2005).
RN   [30]
RP   INTERACTION WITH RANBP2.
RX   PubMed=16332688; DOI=10.1074/jbc.m504994200;
RA   Um J.W., Min D.S., Rhim H., Kim J., Paik S.R., Chung K.C.;
RT   "Parkin ubiquitinates and promotes the degradation of RanBP2.";
RL   J. Biol. Chem. 281:3595-3603(2006).
RN   [31]
RP   INTERACTION WITH SUMO1, AND SUBCELLULAR LOCATION.
RX   PubMed=16955485; DOI=10.1002/jnr.21041;
RA   Um J.W., Chung K.C.;
RT   "Functional modulation of parkin through physical interaction with
RT   SUMO-1.";
RL   J. Neurosci. Res. 84:1543-1554(2006).
RN   [32]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17846173; DOI=10.1083/jcb.200611128;
RA   Olzmann J.A., Li L., Chudaev M.V., Chen J., Perez F.A., Palmiter R.D.,
RA   Chin L.S.;
RT   "Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1
RT   to aggresomes via binding to HDAC6.";
RL   J. Cell Biol. 178:1025-1038(2007).
RN   [33]
RP   FUNCTION IN MITOCHONDRIAL AUTOPHAGY, AND SUBCELLULAR LOCATION.
RX   PubMed=19029340; DOI=10.1083/jcb.200809125;
RA   Narendra D., Tanaka A., Suen D.F., Youle R.J.;
RT   "Parkin is recruited selectively to impaired mitochondria and promotes
RT   their autophagy.";
RL   J. Cell Biol. 183:795-803(2008).
RN   [34]
RP   INTERACTION WITH RNF41, UBIQUITINATION, MUTAGENESIS OF CYS-421, AND
RP   FUNCTION.
RX   PubMed=18541373; DOI=10.1016/j.neulet.2008.05.052;
RA   Yu F., Zhou J.;
RT   "Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced
RT   oxidative stress.";
RL   Neurosci. Lett. 440:4-8(2008).
RN   [35]
RP   FUNCTION, COMPONENT OF A COMPLEX COMPOSED OF PRKN; PARK7 AND PINK1,
RP   SUBCELLULAR LOCATION, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT
RP   PARK2 PRO-42.
RX   PubMed=19229105; DOI=10.1172/jci37617;
RA   Xiong H., Wang D., Chen L., Choo Y.S., Ma H., Tang C., Xia K.,
RA   Jiang W., Ronai Z., Zhuang X., Zhang Z.;
RT   "Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting
RT   unfolded protein degradation.";
RL   J. Clin. Invest. 119:650-660(2009).
RN   [36]
RP   FUNCTION IN PROTECTION OF APOPTOSIS, CHARACTERIZATION OF VARIANTS
RP   PARK2 ASN-161; CYS-256; TRP-275; ARG-418 AND ARG-441, AND DOMAIN.
RX   PubMed=19801972; DOI=10.1038/ncb1981;
RA   da Costa C.A., Sunyach C., Giaime E., West A., Corti O., Brice A.,
RA   Safe S., Abou-Sleiman P.M., Wood N.W., Takahashi H., Goldberg M.S.,
RA   Shen J., Checler F.;
RT   "Transcriptional repression of p53 by parkin and impairment by
RT   mutations associated with autosomal recessive juvenile Parkinson's
RT   disease.";
RL   Nat. Cell Biol. 11:1370-1375(2009).
RN   [37]
RP   INTERACTION WITH PINK1.
RX   PubMed=20798600; DOI=10.4161/auto.6.7.13286;
RA   Geisler S., Holmstrom K.M., Treis A., Skujat D., Weber S.S.,
RA   Fiesel F.C., Kahle P.J., Springer W.;
RT   "The PINK1/Parkin-mediated mitophagy is compromised by PD-associated
RT   mutations.";
RL   Autophagy 6:871-878(2010).
RN   [38]
RP   FUNCTION, INTERACTION WITH BCL2, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANTS PARK2 ASN-161; ARG-240; PHE-431 AND
RP   LEU-437.
RX   PubMed=20889974; DOI=10.1074/jbc.m110.101469;
RA   Chen D., Gao F., Li B., Wang H., Xu Y., Zhu C., Wang G.;
RT   "Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.";
RL   J. Biol. Chem. 285:38214-38223(2010).
RN   [39]
RP   FUNCTION IN MITOCHONDRIAL AUTOPHAGY, SUBCELLULAR LOCATION, INTERACTION
RP   WITH PINK1, AND CHARACTERIZATION OF VARIANTS PARK ASN-415 AND ASP-430.
RX   PubMed=19966284; DOI=10.1073/pnas.0911187107;
RA   Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J.,
RA   May J., Tocilescu M.A., Liu W., Ko H.S., Magrane J., Moore D.J.,
RA   Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S.;
RT   "PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:378-383(2010).
RN   [40]
RP   FUNCTION, INTERACTION WITH ZNF746, AND CHARACTERIZATION OF VARIANTS
RP   PARK2 TRP-275; ASP-430 AND PHE-431.
RX   PubMed=21376232; DOI=10.1016/j.cell.2011.02.010;
RA   Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O.,
RA   Troconso J.C., Dawson V.L., Dawson T.M.;
RT   "PARIS (ZNF746) repression of PGC-1alpha contributes to
RT   neurodegeneration in Parkinson's disease.";
RL   Cell 144:689-702(2011).
RN   [41]
RP   CHARACTERIZATION OF VARIANTS PARK2 PRO-42 AND GLY-289.
RX   PubMed=20889486; DOI=10.1093/hmg/ddq428;
RA   Rose J.M., Novoselov S.S., Robinson P.A., Cheetham M.E.;
RT   "Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1
RT   domain mutant.";
RL   Hum. Mol. Genet. 20:16-27(2011).
RN   [42]
RP   FUNCTION, REACTION MECHANISM, AND INTERACTION WITH UBE2L3.
RX   PubMed=21532592; DOI=10.1038/nature09966;
RA   Wenzel D.M., Lissounov A., Brzovic P.S., Klevit R.E.;
RT   "UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT
RT   hybrids.";
RL   Nature 474:105-108(2011).
RN   [43]
RP   FUNCTION, INTERACTION WITH CHPF, AND SUBCELLULAR LOCATION.
RX   PubMed=22082830; DOI=10.1093/hmg/ddr530;
RA   Kuroda Y., Sako W., Goto S., Sawada T., Uchida D., Izumi Y.,
RA   Takahashi T., Kagawa N., Matsumoto M., Matsumoto M., Takahashi R.,
RA   Kaji R., Mitsui T.;
RT   "Parkin interacts with Klokin1 for mitochondrial import and
RT   maintenance of membrane potential.";
RL   Hum. Mol. Genet. 21:991-1003(2012).
RN   [44]
RP   PHOSPHORYLATION AT SER-65, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23754282; DOI=10.1074/jbc.m113.467530;
RA   Iguchi M., Kujuro Y., Okatsu K., Koyano F., Kosako H., Kimura M.,
RA   Suzuki N., Uchiyama S., Tanaka K., Matsuda N.;
RT   "Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-
RT   dependent phosphorylation.";
RL   J. Biol. Chem. 288:22019-22032(2013).
RN   [45]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH FBXO7.
RX   PubMed=23933751; DOI=10.1038/nn.3489;
RA   Burchell V.S., Nelson D.E., Sanchez-Martinez A., Delgado-Camprubi M.,
RA   Ivatt R.M., Pogson J.H., Randle S.J., Wray S., Lewis P.A., Houlden H.,
RA   Abramov A.Y., Hardy J., Wood N.W., Whitworth A.J., Laman H.,
RA   Plun-Favreau H.;
RT   "The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to
RT   mediate mitophagy.";
RL   Nat. Neurosci. 16:1257-1265(2013).
RN   [46]
RP   INTERACTION WITH BAG4; BAG5; HSPA1L; HSPA1A AND HSPA8.
RX   PubMed=24270810; DOI=10.1038/nature12748;
RA   Hasson S.A., Kane L.A., Yamano K., Huang C.H., Sliter D.A.,
RA   Buehler E., Wang C., Heman-Ackah S.M., Hessa T., Guha R., Martin S.E.,
RA   Youle R.J.;
RT   "High-content genome-wide RNAi screens identify regulators of parkin
RT   upstream of mitophagy.";
RL   Nature 504:291-295(2013).
RN   [47]
RP   FUNCTION IN MITOPHAGY, INTERACTION WITH MFN2, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=23620051; DOI=10.1126/science.1231031;
RA   Chen Y., Dorn G.W. II;
RT   "PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling
RT   damaged mitochondria.";
RL   Science 340:471-475(2013).
RN   [48]
RP   FUNCTION, PHOSPHORYLATION AT SER-65, UBIQUITIN-BINDING, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF SER-65.
RX   PubMed=24660806; DOI=10.1042/bj20140334;
RA   Kazlauskaite A., Kondapalli C., Gourlay R., Campbell D.G.,
RA   Ritorto M.S., Hofmann K., Alessi D.R., Knebel A., Trost M.,
RA   Muqit M.M.;
RT   "Parkin is activated by PINK1-dependent phosphorylation of ubiquitin
RT   at Ser65.";
RL   Biochem. J. 460:127-139(2014).
RN   [49]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=24751536; DOI=10.1083/jcb.201402104;
RA   Kane L.A., Lazarou M., Fogel A.I., Li Y., Yamano K., Sarraf S.A.,
RA   Banerjee S., Youle R.J.;
RT   "PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase
RT   activity.";
RL   J. Cell Biol. 205:143-153(2014).
RN   [50]
RP   FUNCTION, PHOSPHORYLATION AT SER-65, UBIQUITIN-BINDING, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF SER-65 AND TRP-403.
RX   PubMed=24784582; DOI=10.1038/nature13392;
RA   Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M.,
RA   Kimura Y., Tsuchiya H., Yoshihara H., Hirokawa T., Endo T., Fon E.A.,
RA   Trempe J.F., Saeki Y., Tanaka K., Matsuda N.;
RT   "Ubiquitin is phosphorylated by PINK1 to activate parkin.";
RL   Nature 510:162-166(2014).
RN   [51]
RP   FUNCTION.
RX   PubMed=24896179; DOI=10.1038/nature13418;
RA   Bingol B., Tea J.S., Phu L., Reichelt M., Bakalarski C.E., Song Q.,
RA   Foreman O., Kirkpatrick D.S., Sheng M.;
RT   "The mitochondrial deubiquitinase USP30 opposes parkin-mediated
RT   mitophagy.";
RL   Nature 510:370-375(2014).
RN   [52]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=25527291; DOI=10.15252/embj.201489847;
RA   Wauer T., Swatek K.N., Wagstaff J.L., Gladkova C., Pruneda J.N.,
RA   Michel M.A., Gersch M., Johnson C.M., Freund S.M., Komander D.;
RT   "Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain
RT   assembly and hydrolysis.";
RL   EMBO J. 34:307-325(2015).
RN   [53]
RP   FUNCTION.
RX   PubMed=25621951; DOI=10.1038/ncb3097;
RA   Cunningham C.N., Baughman J.M., Phu L., Tea J.S., Yu C., Coons M.,
RA   Kirkpatrick D.S., Bingol B., Corn J.E.;
RT   "USP30 and parkin homeostatically regulate atypical ubiquitin chains
RT   on mitochondria.";
RL   Nat. Cell Biol. 17:160-169(2015).
RN   [54]
RP   STRUCTURE BY NMR OF 1-76, AND INTERACTION WITH PSMD4.
RX   PubMed=12634850; DOI=10.1038/sj.embor.embor764;
RA   Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S.,
RA   Yamada S., Kawahara H., Yokosawa H., Hattori N., Mizuno Y., Tanaka K.,
RA   Kato K.;
RT   "Parkin binds the Rpn10 subunit of 26S proteasomes through its
RT   ubiquitin-like domain.";
RL   EMBO Rep. 4:301-306(2003).
RN   [55]
RP   STRUCTURE BY NMR OF 307-384 IN COMPLEX WITH ZINC IONS,
RP   CHARACTERIZATION OF VARIANT PARK2 PRO-351, MUTAGENESIS OF CYS-332 AND
RP   CYS-365, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17360614; DOI=10.1073/pnas.0610548104;
RA   Beasley S.A., Hristova V.A., Shaw G.S.;
RT   "Structure of the Parkin in-between-ring domain provides insights for
RT   E3-ligase dysfunction in autosomal recessive Parkinson's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3095-3100(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 137-465, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF CYS-431; HIS-433 AND GLU-444.
RX   PubMed=23727886; DOI=10.1038/emboj.2013.125;
RA   Wauer T., Komander D.;
RT   "Structure of the human Parkin ligase domain in an autoinhibited
RT   state.";
RL   EMBO J. 32:2099-2112(2013).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 137-465, ACTIVE SITE,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-431;
RP   HIS-433 AND GLU-444.
RX   PubMed=23770887; DOI=10.1038/ncomms2982;
RA   Riley B.E., Lougheed J.C., Callaway K., Velasquez M., Brecht E.,
RA   Nguyen L., Shaler T., Walker D., Yang Y., Regnstrom K., Diep L.,
RA   Zhang Z., Chiou S., Bova M., Artis D.R., Yao N., Baker J., Yednock T.,
RA   Johnston J.A.;
RT   "Structure and function of Parkin E3 ubiquitin ligase reveals aspects
RT   of RING and HECT ligases.";
RL   Nat. Commun. 4:1982-1982(2013).
RN   [58]
RP   REVIEW ON VARIANTS.
RX   PubMed=14976155; DOI=10.1093/hmg/ddh089;
RA   Mata I.F., Lockhart P.J., Farrer M.J.;
RT   "Parkin genetics: one model for Parkinson's disease.";
RL   Hum. Mol. Genet. 13:R127-R133(2004).
RN   [59]
RP   VARIANT PARK2 ARG-240.
RX   PubMed=9731209; DOI=10.1006/bbrc.1998.9134;
RA   Hattori N., Matsumine H., Asakawa S., Kitada T., Yoshino H.,
RA   Elibol B., Brookes A.J., Yamamura Y., Kobayashi T., Wang M.,
RA   Yoritaka A., Minoshima S., Shimizu N., Mizuno Y.;
RT   "Point mutations (Thr240Arg and Gln311Stop) in the Parkin gene.";
RL   Biochem. Biophys. Res. Commun. 249:754-758(1998).
RN   [60]
RP   ERRATUM.
RA   Hattori N., Matsumine H., Asakawa S., Kitada T., Yoshino H.,
RA   Elibol B., Brookes A.J., Yamamura Y., Kobayashi T., Wang M.,
RA   Yoritaka A., Minoshima S., Shimizu N., Mizuno Y.;
RL   Biochem. Biophys. Res. Commun. 251:666-666(1998).
RN   [61]
RP   VARIANTS PARK2 ASN-161; CYS-256; TRP-275 AND ASN-415, AND VARIANTS
RP   ASN-167; LEU-380 AND ASN-394.
RX   PubMed=10072423; DOI=10.1093/hmg/8.4.567;
RA   Abbas N., Luecking C.B., Ricard S., Duerr A., Bonifati V.,
RA   De Michele G., Bouley S., Vaughan J.R., Gasser T., Marconi R.,
RA   Broussolle E., Brefel-Courbon C., Harhangi B.S., Oostra B.A.,
RA   Fabrizio E., Bohme G.A., Pradier L., Wood N.W., Filla A., Meco G.,
RA   Denefle P., Agid Y., Brice A.;
RT   "A wide variety of mutations in the parkin gene are responsible for
RT   autosomal recessive parkinsonism in Europe.";
RL   Hum. Mol. Genet. 8:567-574(1999).
RN   [62]
RP   VARIANT ASN-167.
RX   PubMed=10511432; DOI=10.1097/00001756-199909090-00008;
RA   Satoh J., Kuroda Y.;
RT   "Association of codon 167 Ser/Asn heterozygosity in the parkin gene
RT   with sporadic Parkinson's disease.";
RL   NeuroReport 10:2735-2739(1999).
RN   [63]
RP   VARIANT PARK2 PHE-431.
RX   PubMed=10939576;
RX   DOI=10.1002/1531-8249(200008)48:2<245::aid-ana15>3.0.co;2-2;
RA   Maruyama M., Ikeuchi T., Saito M., Ishikawa A., Yuasa T., Tanaka H.,
RA   Hayashi S., Wakabayashi K., Takahashi H., Tsuji S.;
RT   "Novel mutations, pseudo-dominant inheritance, and possible familial
RT   affects in patients with autosomal recessive juvenile parkinsonism.";
RL   Ann. Neurol. 48:245-250(2000).
RN   [64]
RP   VARIANTS ASN-167; TRP-366 AND LEU-380.
RX   PubMed=10965160; DOI=10.1159/000008203;
RA   Hu C.-J., Sung S.-M., Liu H.-C., Lee C.-C., Tsai C.-H., Chang J.-G.;
RT   "Polymorphisms of the parkin gene in sporadic Parkinson's disease
RT   among Chinese in Taiwan.";
RL   Eur. Neurol. 44:90-93(2000).
RN   [65]
RP   VARIANTS PARK2 ASN-161; ASN-211; CYS-256; TRP-275; ASN-280; GLY-289;
RP   GLU-328; ASN-415 AND ASP-430, AND VARIANT CYS-334.
RX   PubMed=10824074; DOI=10.1056/nejm200005253422103;
RA   Luecking C.B., Duerr A., Bonifati V., Vaughan J.R., De Michele G.,
RA   Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y.,
RA   Brice A.;
RT   "Association between early-onset Parkinson's disease and mutations in
RT   the parkin gene.";
RL   N. Engl. J. Med. 342:1560-1567(2000).
RN   [66]
RP   VARIANTS PARK2 ASN-211; TRP-275 AND ASP-430.
RX   PubMed=11179010; DOI=10.1086/318791;
RA   Periquet M., Luecking C.B., Vaughan J.R., Bonifati V., Duerr A.,
RA   De Michele G., Horstink M., Farrer M., Illarioshkin S.N., Pollak P.,
RA   Borg M., Brefel-Courbon C., Denefle P., Meco G., Gasser T.,
RA   Breteler M.M., Wood N.W., Agid Y., Brice A.;
RT   "Origin of the mutations in the parkin gene in Europe: exon
RT   rearrangements are independent recurrent events, whereas point
RT   mutations may result from founder effects.";
RL   Am. J. Hum. Genet. 68:617-626(2001).
RN   [67]
RP   VARIANT PARK2 GLU-82.
RX   PubMed=11487568; DOI=10.1093/hmg/10.16.1649;
RA   Hedrich K., Kann M., Lanthaler A.J., Dalski A., Eskelson C., Landt O.,
RA   Schwinger E., Vieregge P., Lang A.E., Breakefield X.O., Ozelius L.J.,
RA   Pramstaller P.P., Klein C.;
RT   "The importance of gene dosage studies: mutational analysis of the
RT   parkin gene in early-onset parkinsonism.";
RL   Hum. Mol. Genet. 10:1649-1656(2001).
RN   [68]
RP   VARIANT PARK2 TYR-212.
RX   PubMed=11163284; DOI=10.1016/s0304-3940(00)01733-x;
RA   Pineda-Trujillo N., Carvajal-Carmona L.G., Buritica O., Moreno S.,
RA   Uribe C., Pineda D., Toro M., Garcia F., Arias W., Bedoya G.,
RA   Lopera F., Ruiz-Linares A.;
RT   "A novel Cys212Tyr founder mutation in parkin and allelic
RT   heterogeneity of juvenile parkinsonism in a population from North West
RT   Colombia.";
RL   Neurosci. Lett. 298:87-90(2001).
RN   [69]
RP   VARIANTS PARK2 GLU-82; CYS-256; TRP-275; GLU-328 AND ARG-441.
RX   PubMed=12116199; DOI=10.1002/ajmg.10525;
RG   French Parkinson's disease genetics study group;
RG   European consortium on genetic susceptibility on Parkinson's disease;
RA   West A., Periquet M., Lincoln S., Luecking C.B., Nicholl D.,
RA   Bonifati V., Rawal N., Gasser T., Lohmann E., Deleuze J.-F.,
RA   Maraganore D., Levey A., Wood N.W., Duerr A., Hardy J., Brice A.,
RA   Farrer M.;
RT   "Complex relationship between parkin mutations and Parkinson
RT   disease.";
RL   Am. J. Med. Genet. 114:584-591(2002).
RN   [70]
RP   ERRATUM.
RG   French Parkinson's disease genetics study group;
RG   European consortium on genetic susceptibility on Parkinson's disease;
RA   West A., Periquet M., Lincoln S., Luecking C.B., Nicholl D.,
RA   Bonifati V., Rawal N., Gasser T., Lohmann E., Deleuze J.-F.,
RA   Maraganore D., Levey A., Wood N.W., Duerr A., Hardy J., Brice A.,
RA   Farrer M.J.;
RL   Am. J. Med. Genet. 114:992-992(2002).
RN   [71]
RP   VARIANTS PARK2 LEU-37 AND PRO-351.
RX   PubMed=12112109; DOI=10.1002/ana.10179;
RA   Kann M., Jacobs H., Mohrmann K., Schumacher K., Hedrich K.,
RA   Garrels J., Wiegers K., Schwinger E., Pramstaller P.P.,
RA   Breakefield X.O., Ozelius L.J., Vieregge P., Klein C.;
RT   "Role of parkin mutations in 111 community-based patients with early-
RT   onset parkinsonism.";
RL   Ann. Neurol. 51:621-625(2002).
RN   [72]
RP   VARIANTS PARK2 GLU-56 AND TYR-212.
RX   PubMed=12056932; DOI=10.1001/archneur.59.6.966;
RA   Hoenicka J., Vidal L., Morales B., Ampuero I., Jimenez-Jimenez F.J.,
RA   Berciano J., del Ser T., Jimenez A., Ruiz P.G., de Yebenes J.G.;
RT   "Molecular findings in familial Parkinson disease in Spain.";
RL   Arch. Neurol. 59:966-970(2002).
RN   [73]
RP   VARIANTS PARK2 ASN-211; TRP-275; ASP-430 AND LEU-437.
RX   PubMed=12114481; DOI=10.1136/jmg.39.7.489;
RA   Nichols W.C., Pankratz N., Uniacke S.K., Pauciulo M.W., Halter C.,
RA   Rudolph A., Conneally P.M., Foroud T.;
RT   "Linkage stratification and mutation analysis at the parkin locus
RT   identifies mutation positive Parkinson's disease families.";
RL   J. Med. Genet. 39:489-492(2002).
RN   [74]
RP   VARIANT PARK2 MET-15, AND VARIANTS LEU-380 AND ASN-394.
RX   PubMed=12397156; DOI=10.1136/jnnp.73.5.582;
RA   Munoz E., Tolosa E., Pastor P., Marti M.J., Valldeoriola F.,
RA   Campdelacreu J., Oliva R.;
RT   "Relative high frequency of the c.255delA parkin gene mutation in
RT   Spanish patients with autosomal recessive parkinsonism.";
RL   J. Neurol. Neurosurg. Psych. 73:582-584(2002).
RN   [75]
RP   VARIANTS PARK2 PRO-42; LEU-192; CYS-256; TRP-275; ASP-430 AND LEU-437.
RX   PubMed=11971093; DOI=10.1212/wnl.58.8.1239;
RA   Hedrich K., Marder K., Harris J., Kann M., Lynch T., Meija-Santana H.,
RA   Pramstaller P.P., Schwinger E., Bressman S.B., Fahn S., Klein C.;
RT   "Evaluation of 50 probands with early-onset Parkinson's disease for
RT   parkin mutations.";
RL   Neurology 58:1239-1246(2002).
RN   [76]
RP   VARIANT PARK2 PRO-46.
RX   PubMed=12362318;
RA   Xu Y., Liu Z., Wang Y., Tao E., Chen G., Chen B.;
RT   "A new point mutation on exon 2 of parkin gene in Parkinson's
RT   disease.";
RL   Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:409-411(2002).
RN   [77]
RP   VARIANTS PARK2 GLN-33; GLU-82; ASP-430 AND LEU-437, VARIANTS PARK
RP   TYR-253; CYS-256; TRP-275 AND ASN-280, AND VARIANTS LEU-380 AND
RP   ASN-394.
RX   PubMed=12730996; DOI=10.1002/ana.10524;
RA   Oliveira S.A., Scott W.K., Martin E.R., Nance M.A., Watts R.L.,
RA   Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Ondo W.G.,
RA   Allen F.H. Jr., Scott B.L., Goetz C.G., Small G.W., Mastaglia F.,
RA   Stajich J.M., Zhang F., Booze M.W., Winn M.P., Middleton L.T.,
RA   Haines J.L., Pericak-Vance M.A., Vance J.M.;
RT   "Parkin mutations and susceptibility alleles in late-onset Parkinson's
RT   disease.";
RL   Ann. Neurol. 53:624-629(2003).
RN   [78]
RP   VARIANTS PARK2 VAL-192; ASN-211; MET-240 AND LEU-437, VARIANT ASN-167,
RP   AND INVOLVEMENT IN LATE-ONSET PARK.
RX   PubMed=12629236; DOI=10.1212/01.wnl.0000049470.00180.07;
RA   Foroud T., Uniacke S.K., Liu L., Pankratz N., Rudolph A., Halter C.,
RA   Shults C., Marder K., Conneally P.M., Nichols W.C.;
RT   "Heterozygosity for a mutation in the parkin gene leads to later onset
RT   Parkinson disease.";
RL   Neurology 60:796-801(2003).
RN   [79]
RP   VARIANTS HIS-100; SER-271 AND SER-339.
RX   PubMed=12781599; DOI=10.1016/s1353-8020(03)00018-x;
RA   Chen R., Gosavi N.S., Langston J.W., Chan P.;
RT   "Parkin mutations are rare in patients with young-onset parkinsonism
RT   in a US population.";
RL   Parkinsonism Relat. Disord. 9:309-312(2003).
RN   [80]
RP   VARIANTS PARK2 PRO-42; CYS-402; ASN-415 AND ARG-418.
RX   PubMed=15584030; DOI=10.1002/mds.20343;
RG   Italian Parkinson Genetics Network;
RA   Bertoli-Avella A.M., Giroud-Benitez J.L., Akyol A., Barbosa E.,
RA   Schaap O., van der Linde H.C., Martignoni E., Lopiano L., Lamberti P.,
RA   Fincati E., Antonini A., Stocchi F., Montagna P., Squitieri F.,
RA   Marini P., Abbruzzese G., Fabbrini G., Marconi R., Dalla Libera A.,
RA   Trianni G., Guidi M., De Gaetano A., Boff Maegawa G., De Leo A.,
RA   Gallai V., de Rosa G., Vanacore N., Meco G., van Duijn C.M.,
RA   Oostra B.A., Heutink P., Bonifati V.;
RT   "Novel parkin mutations detected in patients with early-onset
RT   Parkinson's disease.";
RL   Mov. Disord. 20:424-431(2005).
RN   [81]
RP   CHARACTERIZATION OF VARIANTS PARK2 ASN-161; ASN-211; ARG-240; ASN-280
RP   AND GLU-328.
RX   PubMed=20404107; DOI=10.1083/jcb.200910140;
RA   Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A.,
RA   Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M.,
RA   Hattori N., Tanaka K.;
RT   "PINK1 stabilized by mitochondrial depolarization recruits Parkin to
RT   damaged mitochondria and activates latent Parkin for mitophagy.";
RL   J. Cell Biol. 189:211-221(2010).
RN   [82]
RP   VARIANT PARK2 TRP-275.
RX   PubMed=22956510; DOI=10.1002/mds.25132;
RA   Kilarski L.L., Pearson J.P., Newsway V., Majounie E., Knipe M.D.,
RA   Misbahuddin A., Chinnery P.F., Burn D.J., Clarke C.E., Marion M.H.,
RA   Lewthwaite A.J., Nicholl D.J., Wood N.W., Morrison K.E.,
RA   Williams-Gray C.H., Evans J.R., Sawcer S.J., Barker R.A.,
RA   Wickremaratchi M.M., Ben-Shlomo Y., Williams N.M., Morris H.R.;
RT   "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7
RT   (DJ-1) and LRRK2 in early-onset Parkinson's disease.";
RL   Mov. Disord. 27:1522-1529(2012).
RN   [83]
RP   VARIANT CYS-334.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E.,
RA   Fennell T., O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B.,
RA   Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K.,
RA   Zhao F., Zou J., Pierce-Hoffman E., Berghout J., Cooper D.N.,
RA   Deflaux N., DePristo M., Do R., Flannick J., Fromer M., Gauthier L.,
RA   Goldstein J., Gupta N., Howrigan D., Kiezun A., Kurki M.I.,
RA   Moonshine A.L., Natarajan P., Orozco L., Peloso G.M., Poplin R.,
RA   Rivas M.A., Ruano-Rubio V., Rose S.A., Ruderfer D.M., Shakir K.,
RA   Stenson P.D., Stevens C., Thomas B.P., Tiao G., Tusie-Luna M.T.,
RA   Weisburd B., Won H.H., Yu D., Altshuler D.M., Ardissino D.,
RA   Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S.,
RA   Laakso M., McCarroll S., McCarthy M.I., McGovern D., McPherson R.,
RA   Neale B.M., Palotie A., Purcell S.M., Saleheen D., Scharf J.M.,
RA   Sklar P., Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C.,
RA   Wilson J.G., Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
RN   [84]
RP   CHARACTERIZATION OF VARIANTS PARK PRO-42 AND TRP-275, AND FUNCTION.
RX   PubMed=29311685; DOI=10.1038/s41467-017-02593-y;
RA   Wang C., Kang X., Zhou L., Chai Z., Wu Q., Huang R., Xu H., Hu M.,
RA   Sun X., Sun S., Li J., Jiao R., Zuo P., Zheng L., Yue Z., Zhou Z.;
RT   "Synaptotagmin-11 is a critical mediator of parkin-linked
RT   neurotoxicity and Parkinson's disease-like pathology.";
RL   Nat. Commun. 9:81-81(2018).
CC   -!- FUNCTION: Functions within a multiprotein E3 ubiquitin ligase
CC       complex, catalyzing the covalent attachment of ubiquitin moieties
CC       onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37,
CC       RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30,
CC       ZNF746 and AIMP2 (PubMed:10973942, PubMed:10888878,
CC       PubMed:11431533, PubMed:12150907, PubMed:12628165,
CC       PubMed:16135753, PubMed:21376232, PubMed:23754282,
CC       PubMed:23620051, PubMed:24660806, PubMed:24751536,
CC       PubMed:29311685). Mediates monoubiquitination as well as 'Lys-6',
CC       'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination
CC       of substrates depending on the context (PubMed:19229105,
CC       PubMed:20889974, PubMed:25621951). Participates in the removal
CC       and/or detoxification of abnormally folded or damaged protein by
CC       mediating 'Lys-63'-linked polyubiquitination of misfolded proteins
CC       such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded
CC       proteins are then recognized by HDAC6, leading to their
CC       recruitment to aggresomes, followed by degradation
CC       (PubMed:17846173, PubMed:19229105). Mediates 'Lys-63'-linked
CC       polyubiquitination of a 22 kDa O-linked glycosylated isoform of
CC       SNCAIP, possibly playing a role in Lewy-body formation
CC       (PubMed:11590439, PubMed:11431533, PubMed:19229105,
CC       PubMed:11590439, PubMed:15728840). Mediates monoubiquitination of
CC       BCL2, thereby acting as a positive regulator of autophagy
CC       (PubMed:20889974). Promotes the autophagic degradation of
CC       dysfunctional depolarized mitochondria (mitophagy) by promoting
CC       the ubiquitination of mitochondrial proteins such as TOMM20,
CC       RHOT1/MIRO1 and USP30 (PubMed:19029340, PubMed:19966284,
CC       PubMed:23620051, PubMed:24896179, PubMed:25527291). Preferentially
CC       assembles 'Lys-6'-, 'Lys-11'- and 'Lys-63'-linked polyubiquitin
CC       chains following mitochondrial damage, leading to mitophagy
CC       (PubMed:25621951). Mediates 'Lys-48'-linked polyubiquitination of
CC       ZNF746, followed by degradation of ZNF746 by the proteasome;
CC       possibly playing a role in the regulation of neuron death
CC       (PubMed:21376232). Limits the production of reactive oxygen
CC       species (ROS). Regulates cyclin-E during neuronal apoptosis. In
CC       collaboration with CHPF isoform 2, may enhance cell viability and
CC       protect cells from oxidative stress (PubMed:22082830).
CC       Independently of its ubiquitin ligase activity, protects from
CC       apoptosis by the transcriptional repression of p53/TP53
CC       (PubMed:19801972). May protect neurons against alpha synuclein
CC       toxicity, proteasomal dysfunction, GPR37 accumulation, and
CC       kainate-induced excitotoxicity (PubMed:11439185). May play a role
CC       in controlling neurotransmitter trafficking at the presynaptic
CC       terminal and in calcium-dependent exocytosis. May represent a
CC       tumor suppressor gene. {ECO:0000269|PubMed:10888878,
CC       ECO:0000269|PubMed:10973942, ECO:0000269|PubMed:11431533,
CC       ECO:0000269|PubMed:11590439, ECO:0000269|PubMed:12628165,
CC       ECO:0000269|PubMed:12719539, ECO:0000269|PubMed:15105460,
CC       ECO:0000269|PubMed:15728840, ECO:0000269|PubMed:16135753,
CC       ECO:0000269|PubMed:17846173, ECO:0000269|PubMed:18541373,
CC       ECO:0000269|PubMed:19029340, ECO:0000269|PubMed:19229105,
CC       ECO:0000269|PubMed:19801972, ECO:0000269|PubMed:19966284,
CC       ECO:0000269|PubMed:20889974, ECO:0000269|PubMed:21376232,
CC       ECO:0000269|PubMed:21532592, ECO:0000269|PubMed:22082830,
CC       ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:23754282,
CC       ECO:0000269|PubMed:23933751, ECO:0000269|PubMed:24660806,
CC       ECO:0000269|PubMed:24751536, ECO:0000269|PubMed:24784582,
CC       ECO:0000269|PubMed:24896179, ECO:0000269|PubMed:25527291,
CC       ECO:0000269|PubMed:25621951, ECO:0000269|PubMed:29311685}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-
CC         cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC         conjugating enzyme]-L-cysteine + [acceptor protein]-N(6)-
CC         ubiquitinyl-L-lysine.; EC=2.3.2.31;
CC         Evidence={ECO:0000269|PubMed:23770887};
CC   -!- ACTIVITY REGULATION: In the autoinhibited state the side chain of
CC       Phe-463 inserts into a hydrophobic groove in RING-0, occluding the
CC       ubiquitin acceptor site Cys-431, whereas the REP repressor element
CC       binds RING-1 and blocks its E2-binding site (PubMed:23727886,
CC       PubMed:23770887). Activation of PRKN requires 2 steps: (1)
CC       phosphorylation at Ser-65 by PINK1 and (2) binding to
CC       phosphorylated ubiquitin, leading to unlock repression of the
CC       catalytic Cys-431 by the RING-0 region via an allosteric mechanism
CC       and converting PRKN to its fully-active form (PubMed:24660806,
CC       PubMed:24784582, PubMed:25527291). According to another report,
CC       phosphorylation at Ser-65 by PINK1 is not essential for activation
CC       and only binding to phosphorylated ubiquitin is essential to
CC       unlock repression (PubMed:24751536). {ECO:0000269|PubMed:23727886,
CC       ECO:0000269|PubMed:23770887, ECO:0000269|PubMed:24660806,
CC       ECO:0000269|PubMed:24751536, ECO:0000269|PubMed:24784582,
CC       ECO:0000269|PubMed:25527291}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Forms an E3 ubiquitin ligase complex with UBE2L3 or
CC       UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating
CC       with UBE2V1. Part of a SCF-like complex, consisting of PRKN, CUL1
CC       and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains
CC       of SYT11. Interacts and regulates the turnover of SEPTIN5. Part of
CC       a complex, including STUB1, HSP70 and GPR37. The amount of STUB1
CC       in the complex increases during ER stress. STUB1 promotes the
CC       dissociation of HSP70 from PRKN and GPR37, thus facilitating PRKN-
CC       mediated GPR37 ubiquitination. HSP70 transiently associates with
CC       unfolded GPR37 and inhibits the E3 activity of PRKN, whereas,
CC       STUB1 enhances the E3 activity of PRKN through promotion of
CC       dissociation of HSP70 from PRKN-GPR37 complexes. Interacts with
CC       PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2.
CC       Interacts with SUMO1 but not SUMO2, which promotes nuclear
CC       localization and autoubiquitination. Interacts (via first RING-
CC       type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and
CC       RNF41. Interacts with PINK1. Interacts with CHPF, the interaction
CC       with isoform 2 may facilitate PRKN transport into the
CC       mitochondria. Interacts with MFN2 (phosphorylated), promotes PRKN
CC       localization in dysfunctional depolarized mitochondria. Interacts
CC       with FBXO7; this promotes translocation to dysfunctional
CC       depolarized mitochondria. Interacts with heat shock protein 70
CC       family members, including HSPA1L, HSPA1A and HSPA8; interaction
CC       HSPA1L promotes translocation to damaged mitochondria. Interacts
CC       with BAG4 and, to a lesser extent, BAG5; interaction with BAG4
CC       inhibits translocation to damaged mitochondria. Forms a complex
CC       with PINK1 and PARK7 (PubMed:19229105).
CC       {ECO:0000269|PubMed:11078524, ECO:0000269|PubMed:11590439,
CC       ECO:0000269|PubMed:12150907, ECO:0000269|PubMed:12628165,
CC       ECO:0000269|PubMed:12634850, ECO:0000269|PubMed:12925569,
CC       ECO:0000269|PubMed:14532270, ECO:0000269|PubMed:15728840,
CC       ECO:0000269|PubMed:15987638, ECO:0000269|PubMed:16135753,
CC       ECO:0000269|PubMed:16332688, ECO:0000269|PubMed:16352719,
CC       ECO:0000269|PubMed:16955485, ECO:0000269|PubMed:17360614,
CC       ECO:0000269|PubMed:18541373, ECO:0000269|PubMed:19229105,
CC       ECO:0000269|PubMed:19966284, ECO:0000269|PubMed:20798600,
CC       ECO:0000269|PubMed:20889974, ECO:0000269|PubMed:21376232,
CC       ECO:0000269|PubMed:21532592, ECO:0000269|PubMed:22082830,
CC       ECO:0000269|PubMed:23620051, ECO:0000269|PubMed:23933751,
CC       ECO:0000269|PubMed:24270810}.
CC   -!- INTERACTION:
CC       O60260; O60260-2; NbExp=5; IntAct=EBI-716346, EBI-716346;
CC       O60260; Q99IB8; Xeno; NbExp=3; IntAct=EBI-716346, EBI-6858513;
CC       O60260; P54252-2: ATXN3; NbExp=5; IntAct=EBI-716346, EBI-9684323;
CC       O60260; Q8IZ52-2: CHPF; NbExp=5; IntAct=EBI-716346, EBI-9029620;
CC       O60260; Q9Y3I1: FBXO7; NbExp=10; IntAct=EBI-716346, EBI-1161222;
CC       O60260; Q9Y3I1-1: FBXO7; NbExp=2; IntAct=EBI-716346, EBI-9102965;
CC       O60260; Q9UBN7: HDAC6; NbExp=6; IntAct=EBI-716346, EBI-301697;
CC       O60260; P08238: HSP90AB1; NbExp=2; IntAct=EBI-716346, EBI-352572;
CC       O60260; Q5S007: LRRK2; NbExp=3; IntAct=EBI-716346, EBI-5323863;
CC       O60260; O95140: MFN2; NbExp=4; IntAct=EBI-716346, EBI-3324756;
CC       O60260; Q16342: PDCD2; NbExp=5; IntAct=EBI-716346, EBI-359462;
CC       O60260; Q9BXM7: PINK1; NbExp=7; IntAct=EBI-716346, EBI-2846068;
CC       O60260; Q9BXM7-1: PINK1; NbExp=2; IntAct=EBI-716346, EBI-15643376;
CC       O60260; P49792: RANBP2; NbExp=11; IntAct=EBI-716346, EBI-973138;
CC       O60260; Q8IXI2: RHOT1; NbExp=3; IntAct=EBI-716346, EBI-1396430;
CC       O60260; Q9Z2Q6: Septin5; Xeno; NbExp=2; IntAct=EBI-716346, EBI-772125;
CC       O60260; Q15645: TRIP13; NbExp=4; IntAct=EBI-716346, EBI-358993;
CC       O60260; P68510: Ywhah; Xeno; NbExp=6; IntAct=EBI-716346, EBI-444641;
CC       O60260; Q6NUN9: ZNF746; NbExp=6; IntAct=EBI-716346, EBI-3862525;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:19229105}. Nucleus. Endoplasmic reticulum.
CC       Mitochondrion {ECO:0000269|PubMed:19229105}. Note=Mainly localizes
CC       in the cytosol. Co-localizes with SYT11 in neutrites. Co-localizes
CC       with SNCAIP in brainstem Lewy bodies. Mitochondrial localization
CC       gradually increases with cellular growth. Also relocates to
CC       dysfunctional mitochondria that have lost the mitochondrial
CC       membrane potential; recruitment to mitochondria is PINK1-
CC       dependent.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1;
CC         IsoId=O60260-1; Sequence=Displayed;
CC       Name=2; Synonyms=SV5DEL;
CC         IsoId=O60260-2; Sequence=VSP_011707;
CC       Name=3;
CC         IsoId=O60260-3; Sequence=VSP_011706, VSP_011709, VSP_011710;
CC       Name=4;
CC         IsoId=O60260-4; Sequence=VSP_011705;
CC       Name=5;
CC         IsoId=O60260-5; Sequence=VSP_011708, VSP_011711, VSP_011712;
CC       Name=6;
CC         IsoId=O60260-6; Sequence=VSP_041563;
CC       Name=7; Synonyms=SV5,9DEL;
CC         IsoId=O60260-7; Sequence=VSP_011707, VSP_053651;
CC       Name=8; Synonyms=SV9DEL;
CC         IsoId=O60260-8; Sequence=VSP_053651;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain including the
CC       substantia nigra. Expressed in heart, testis and skeletal muscle.
CC       Expression is down-regulated or absent in tumor biopsies, and
CC       absent in the brain of PARK2 patients. Overexpression protects
CC       dopamine neurons from kainate-mediated apoptosis. Found in serum
CC       (at protein level). {ECO:0000269|PubMed:19501131}.
CC   -!- DOMAIN: The ubiquitin-like domain binds the PSMD4 subunit of 26S
CC       proteasomes. {ECO:0000269|PubMed:19801972}.
CC   -!- DOMAIN: The RING-type 1 zinc finger domain is required to repress
CC       p53/TP53 transcription. {ECO:0000269|PubMed:19801972}.
CC   -!- DOMAIN: Members of the RBR family are atypical E3 ligases. They
CC       interact with the E2 conjugating enzyme UBE2L3 and function like
CC       HECT-type E3 enzymes: they bind E2s via the first RING domain, but
CC       require an obligate trans-thiolation step during the ubiquitin
CC       transfer, requiring a conserved cysteine residue in the second
CC       RING domain (PubMed:21532592). {ECO:0000305|PubMed:21532592}.
CC   -!- PTM: Auto-ubiquitinates in an E2-dependent manner leading to its
CC       own degradation (PubMed:19229105). Also polyubiquitinated by RNF41
CC       for proteasomal degradation. {ECO:0000269|PubMed:19229105}.
CC   -!- PTM: S-nitrosylated. The inhibition of PRKN ubiquitin E3 ligase
CC       activity by S-nitrosylation could contribute to the degenerative
CC       process in PD by impairing the ubiquitination of PRKN substrates.
CC       {ECO:0000269|PubMed:15105460}.
CC   -!- PTM: Phosphorylation at Ser-65 by PINK1 contributes to activate
CC       PRKN activity. It is however not sufficient and requires binding
CC       to phosphorylated ubiquitin as well. {ECO:0000269|PubMed:23754282,
CC       ECO:0000269|PubMed:24660806, ECO:0000269|PubMed:24784582}.
CC   -!- DISEASE: Parkinson disease (PARK) [MIM:168600]: A complex
CC       neurodegenerative disorder characterized by bradykinesia, resting
CC       tremor, muscular rigidity and postural instability. Additional
CC       features are characteristic postural abnormalities, dysautonomia,
CC       dystonic cramps, and dementia. The pathology of Parkinson disease
CC       involves the loss of dopaminergic neurons in the substantia nigra
CC       and the presence of Lewy bodies (intraneuronal accumulations of
CC       aggregated proteins), in surviving neurons in various areas of the
CC       brain. The disease is progressive and usually manifests after the
CC       age of 50 years, although early-onset cases (before 50 years) are
CC       known. The majority of the cases are sporadic suggesting a
CC       multifactorial etiology based on environmental and genetic
CC       factors. However, some patients present with a positive family
CC       history for the disease. Familial forms of the disease usually
CC       begin at earlier ages and are associated with atypical clinical
CC       features. {ECO:0000269|PubMed:12629236,
CC       ECO:0000269|PubMed:12730996, ECO:0000269|PubMed:19966284,
CC       ECO:0000269|PubMed:29311685}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry. Heterozygous mutations act as susceptibility alleles for
CC       late-onset Parkinson disease (PubMed:12730996 and
CC       PubMed:12629236).
CC   -!- DISEASE: Parkinson disease 2 (PARK2) [MIM:600116]: A
CC       neurodegenerative disorder characterized by bradykinesia,
CC       rigidity, postural instability, tremor, and onset usually before
CC       40. It differs from classic Parkinson disease by early DOPA-
CC       induced dyskinesia, diurnal fluctuation of the symptoms, sleep
CC       benefit, dystonia and hyper-reflexia. Dementia is absent.
CC       Pathologically, patients show loss of dopaminergic neurons in the
CC       substantia nigra, similar to that seen in Parkinson disease;
CC       however, Lewy bodies (intraneuronal accumulations of aggregated
CC       proteins) are absent. {ECO:0000269|PubMed:10072423,
CC       ECO:0000269|PubMed:10824074, ECO:0000269|PubMed:10888878,
CC       ECO:0000269|PubMed:10939576, ECO:0000269|PubMed:11163284,
CC       ECO:0000269|PubMed:11179010, ECO:0000269|PubMed:11431533,
CC       ECO:0000269|PubMed:11487568, ECO:0000269|PubMed:11590439,
CC       ECO:0000269|PubMed:11971093, ECO:0000269|PubMed:12056932,
CC       ECO:0000269|PubMed:12112109, ECO:0000269|PubMed:12114481,
CC       ECO:0000269|PubMed:12116199, ECO:0000269|PubMed:12362318,
CC       ECO:0000269|PubMed:12397156, ECO:0000269|PubMed:12629236,
CC       ECO:0000269|PubMed:12730996, ECO:0000269|PubMed:12925569,
CC       ECO:0000269|PubMed:15584030, ECO:0000269|PubMed:17360614,
CC       ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:19801972,
CC       ECO:0000269|PubMed:20404107, ECO:0000269|PubMed:20889486,
CC       ECO:0000269|PubMed:20889974, ECO:0000269|PubMed:21376232,
CC       ECO:0000269|PubMed:22956510, ECO:0000269|PubMed:9560156,
CC       ECO:0000269|PubMed:9731209}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in PRKN may be involved in the development
CC       and/or progression of ovarian cancer.
CC   -!- MISCELLANEOUS: The parkin locus (PRKN), adjacent to the 6q
CC       telomere is hyper-recombinable and lies within FRA6E, the third
CC       most common fragile site in tumor tissue.
CC   -!- SIMILARITY: Belongs to the RBR family. Parkin subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Life's tremors - Issue
CC       131 of September 2011;
CC       URL="https://web.expasy.org/spotlight/back_issues/131";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AB009973; BAA25751.1; -; mRNA.
DR   EMBL; EF375726; ABN46990.1; -; mRNA.
DR   EMBL; AF381282; AAM21457.1; -; mRNA.
DR   EMBL; AF381283; AAM21458.1; -; mRNA.
DR   EMBL; AF381286; AAM21461.1; -; mRNA.
DR   EMBL; GU345839; ADB90270.1; -; mRNA.
DR   EMBL; GU345840; ADB90271.1; -; mRNA.
DR   EMBL; GU361467; ADB91979.1; -; mRNA.
DR   EMBL; AK292590; BAF85279.1; -; mRNA.
DR   EMBL; AL035697; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL132982; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445215; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000886; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000887; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001576; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001577; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001578; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003699; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47573.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47574.1; -; Genomic_DNA.
DR   EMBL; BC022014; AAH22014.1; -; mRNA.
DR   EMBL; AY564225; AAS88422.1; -; Genomic_DNA.
DR   CCDS; CCDS5281.1; -. [O60260-1]
DR   CCDS; CCDS5282.1; -. [O60260-2]
DR   CCDS; CCDS5283.1; -. [O60260-6]
DR   RefSeq; NP_004553.2; NM_004562.2. [O60260-1]
DR   RefSeq; NP_054642.2; NM_013987.2. [O60260-2]
DR   RefSeq; NP_054643.2; NM_013988.2. [O60260-6]
DR   PDB; 1IYF; NMR; -; A=1-76.
DR   PDB; 2JMO; NMR; -; A=308-384.
DR   PDB; 4BM9; X-ray; 2.25 A; A=137-465.
DR   PDB; 4I1F; X-ray; 1.58 A; A=141-465.
DR   PDB; 4I1H; X-ray; 2.00 A; A=141-465.
DR   PDB; 5C1Z; X-ray; 1.79 A; A/B=1-465.
DR   PDB; 5C23; X-ray; 2.37 A; A/B=1-465.
DR   PDB; 5C9V; X-ray; 2.35 A; A=137-465.
DR   PDB; 5N2W; X-ray; 2.68 A; A=1-465.
DR   PDB; 5N38; X-ray; 2.60 A; A=1-465.
DR   PDB; 5TR5; NMR; -; A=1-76.
DR   PDB; 6GLC; X-ray; 1.80 A; A=1-382.
DR   PDB; 6HUE; X-ray; 2.85 A; A/B=1-465.
DR   PDB; 6N13; NMR; -; B=144-465.
DR   PDBsum; 1IYF; -.
DR   PDBsum; 2JMO; -.
DR   PDBsum; 4BM9; -.
DR   PDBsum; 4I1F; -.
DR   PDBsum; 4I1H; -.
DR   PDBsum; 5C1Z; -.
DR   PDBsum; 5C23; -.
DR   PDBsum; 5C9V; -.
DR   PDBsum; 5N2W; -.
DR   PDBsum; 5N38; -.
DR   PDBsum; 5TR5; -.
DR   PDBsum; 6GLC; -.
DR   PDBsum; 6HUE; -.
DR   PDBsum; 6N13; -.
DR   SMR; O60260; -.
DR   BioGRID; 111105; 472.
DR   CORUM; O60260; -.
DR   DIP; DIP-37655N; -.
DR   IntAct; O60260; 130.
DR   MINT; O60260; -.
DR   STRING; 9606.ENSP00000355865; -.
DR   iPTMnet; O60260; -.
DR   PhosphoSitePlus; O60260; -.
DR   BioMuta; PRKN; -.
DR   MassIVE; O60260; -.
DR   PaxDb; O60260; -.
DR   PeptideAtlas; O60260; -.
DR   PRIDE; O60260; -.
DR   ProteomicsDB; 49290; -. [O60260-1]
DR   ProteomicsDB; 49291; -. [O60260-2]
DR   ProteomicsDB; 49292; -. [O60260-3]
DR   ProteomicsDB; 49293; -. [O60260-4]
DR   ProteomicsDB; 49294; -. [O60260-5]
DR   ProteomicsDB; 49295; -. [O60260-6]
DR   DNASU; 5071; -.
DR   Ensembl; ENST00000338468; ENSP00000343589; ENSG00000185345. [O60260-4]
DR   Ensembl; ENST00000366894; ENSP00000355860; ENSG00000185345. [O60260-4]
DR   Ensembl; ENST00000366896; ENSP00000355862; ENSG00000185345. [O60260-6]
DR   Ensembl; ENST00000366897; ENSP00000355863; ENSG00000185345. [O60260-2]
DR   Ensembl; ENST00000366898; ENSP00000355865; ENSG00000185345. [O60260-1]
DR   Ensembl; ENST00000479615; ENSP00000434414; ENSG00000185345. [O60260-3]
DR   GeneID; 5071; -.
DR   KEGG; hsa:5071; -.
DR   UCSC; uc003qty.5; human. [O60260-1]
DR   CTD; 5071; -.
DR   DisGeNET; 5071; -.
DR   GeneCards; PRKN; -.
DR   GeneReviews; PRKN; -.
DR   HGNC; HGNC:8607; PRKN.
DR   HPA; CAB016257; -.
DR   HPA; HPA036012; -.
DR   MalaCards; PRKN; -.
DR   MIM; 168600; phenotype.
DR   MIM; 600116; phenotype.
DR   MIM; 602544; gene.
DR   neXtProt; NX_O60260; -.
DR   OpenTargets; ENSG00000185345; -.
DR   Orphanet; 2828; Young-onset Parkinson disease.
DR   PharmGKB; PA32942; -.
DR   eggNOG; KOG0006; Eukaryota.
DR   eggNOG; ENOG410YG4B; LUCA.
DR   GeneTree; ENSGT00390000011034; -.
DR   HOGENOM; HOG000013184; -.
DR   InParanoid; O60260; -.
DR   OMA; IGYSLPC; -.
DR   OrthoDB; 716326at2759; -.
DR   PhylomeDB; O60260; -.
DR   TreeFam; TF314529; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-5205685; Pink/Parkin Mediated Mitophagy.
DR   Reactome; R-HSA-5689877; Josephin domain DUBs.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; O60260; -.
DR   SIGNOR; O60260; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; PARK2; human.
DR   EvolutionaryTrace; O60260; -.
DR   GeneWiki; Parkin_(ligase); -.
DR   GenomeRNAi; 5071; -.
DR   Pharos; O60260; -.
DR   PRO; PR:O60260; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000185345; Expressed in 111 organ(s), highest expression level in frontal cortex.
DR   ExpressionAtlas; O60260; baseline and differential.
DR   Genevisible; O60260; HS.
DR   GO; GO:0016235; C:aggresome; IDA:BHF-UCL.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0097413; C:Lewy body; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990452; C:Parkin-FBXW7-Cul1 ubiquitin ligase complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0097602; F:cullin family protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:1990444; F:F-box domain binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:BHF-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0015631; F:tubulin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0070842; P:aggresome assembly; IMP:BHF-UCL.
DR   GO; GO:0000422; P:autophagy of mitochondrion; IDA:UniProtKB.
DR   GO; GO:0044257; P:cellular protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:1903351; P:cellular response to dopamine; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0071287; P:cellular response to manganese ion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0097237; P:cellular response to toxic substance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0034620; P:cellular response to unfolded protein; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0042417; P:dopamine metabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0051583; P:dopamine uptake involved in synaptic transmission; IEA:Ensembl.
DR   GO; GO:0036503; P:ERAD pathway; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0010994; P:free ubiquitin chain polymerization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0000266; P:mitochondrial fission; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0099074; P:mitochondrion to lysosome transport; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000423; P:mitophagy; IEA:Ensembl.
DR   GO; GO:0044828; P:negative regulation by host of viral genome replication; IDA:AgBase.
DR   GO; GO:0032232; P:negative regulation of actin filament bundle assembly; IDA:BHF-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060548; P:negative regulation of cell death; IDA:BHF-UCL.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903382; P:negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1903542; P:negative regulation of exosomal secretion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0033132; P:negative regulation of glucokinase activity; IDA:MGI.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IDA:MGI.
DR   GO; GO:1905366; P:negative regulation of intralumenal vesicle formation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010637; P:negative regulation of mitochondrial fusion; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1903202; P:negative regulation of oxidative stress-induced cell death; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1902283; P:negative regulation of primary amine oxidase activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IDA:BHF-UCL.
DR   GO; GO:1904049; P:negative regulation of spontaneous neurotransmitter secretion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0070050; P:neuron cellular homeostasis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0042415; P:norepinephrine metabolic process; IEA:Ensembl.
DR   GO; GO:0061734; P:parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903599; P:positive regulation of autophagy of mitochondrion; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010636; P:positive regulation of mitochondrial fusion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0098779; P:positive regulation of mitophagy in response to mitochondrial depolarization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051582; P:positive regulation of neurotransmitter uptake; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1901800; P:positive regulation of proteasomal protein catabolic process; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1902530; P:positive regulation of protein linear polyubiquitination; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1905477; P:positive regulation of protein localization to membrane; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905281; P:positive regulation of retrograde transport, endosome to Golgi; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010498; P:proteasomal protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0070979; P:protein K11-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0044314; P:protein K27-linked ubiquitination; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0035519; P:protein K29-linked ubiquitination; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070585; P:protein localization to mitochondrion; IEA:Ensembl.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0010506; P:regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014059; P:regulation of dopamine secretion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0032368; P:regulation of lipid transport; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl.
DR   GO; GO:0010821; P:regulation of mitochondrion organization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903214; P:regulation of protein targeting to mitochondrion; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IMP:ParkinsonsUK-UCL.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:UniProtKB.
DR   GO; GO:1902803; P:regulation of synaptic vesicle transport; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006979; P:response to oxidative stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0001964; P:startle response; IEA:Ensembl.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0055069; P:zinc ion homeostasis; ISS:ParkinsonsUK-UCL.
DR   DisProt; DP01849; -.
DR   InterPro; IPR031127; E3_UB_ligase_RBR.
DR   InterPro; IPR002867; IBR_dom.
DR   InterPro; IPR003977; Parkin.
DR   InterPro; IPR041565; Parkin_Znf-RING.
DR   InterPro; IPR000626; Ubiquitin-like_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   InterPro; IPR041170; Znf-RING_14.
DR   PANTHER; PTHR11685; PTHR11685; 1.
DR   Pfam; PF01485; IBR; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   Pfam; PF17976; zf-RING_12; 1.
DR   Pfam; PF17978; zf-RING_14; 1.
DR   PIRSF; PIRSF037880; Parkin; 1.
DR   PRINTS; PR01475; PARKIN.
DR   SMART; SM00647; IBR; 2.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS51873; TRIAD; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure.
FT   CHAIN         1    465       E3 ubiquitin-protein ligase parkin.
FT                                /FTId=PRO_0000058576.
FT   DOMAIN        1     76       Ubiquitin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00214}.
FT   ZN_FING     141    225       RING-type 0; atypical.
FT   ZN_FING     238    293       RING-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   ZN_FING     313    377       IBR-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   ZN_FING     418    449       RING-type 2; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01221}.
FT   REGION      204    238       SYT11 binding 1.
FT                                {ECO:0000269|PubMed:12925569}.
FT   REGION      234    465       TRIAD supradomain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   REGION      257    293       SYT11 binding 2.
FT                                {ECO:0000269|PubMed:12925569}.
FT   REGION      378    410       REP. {ECO:0000250}.
FT   ACT_SITE    431    431       {ECO:0000255|PROSITE-ProRule:PRU01221}.
FT   METAL       238    238       Zinc 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       241    241       Zinc 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       253    253       Zinc 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       257    257       Zinc 2; via pros nitrogen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01221}.
FT   METAL       260    260       Zinc 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       263    263       Zinc 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       289    289       Zinc 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       293    293       Zinc 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       332    332       Zinc 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       337    337       Zinc 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       352    352       Zinc 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       360    360       Zinc 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       365    365       Zinc 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       368    368       Zinc 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       373    373       Zinc 4; via tele nitrogen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01221}.
FT   METAL       377    377       Zinc 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       418    418       Zinc 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       421    421       Zinc 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       436    436       Zinc 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       441    441       Zinc 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       446    446       Zinc 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       449    449       Zinc 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       457    457       Zinc 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01221}.
FT   METAL       461    461       Zinc 6; via tele nitrogen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01221}.
FT   MOD_RES      65     65       Phosphoserine; by PINK1.
FT                                {ECO:0000269|PubMed:23754282,
FT                                ECO:0000269|PubMed:24660806,
FT                                ECO:0000269|PubMed:24784582}.
FT   VAR_SEQ       1    191       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_011705.
FT   VAR_SEQ       1     79       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_011706.
FT   VAR_SEQ      58    206       Missing (in isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_041563.
FT   VAR_SEQ     179    206       Missing (in isoform 2 and isoform 7).
FT                                {ECO:0000303|PubMed:9560156,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_011707.
FT   VAR_SEQ     290    290       V -> VGTGDTVVLRGALGGFRRGV (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011708.
FT   VAR_SEQ     291    297       AGCPNSL -> VCLLPGM (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_011709.
FT   VAR_SEQ     298    465       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_011710.
FT   VAR_SEQ     312    361       Missing (in isoform 7 and isoform 8).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_053651.
FT   VAR_SEQ     362    368       FAFCREC -> YGQRRTK (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011711.
FT   VAR_SEQ     369    465       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011712.
FT   VARIANT      15     15       V -> M (in PARK2; dbSNP:rs532703934).
FT                                {ECO:0000269|PubMed:12397156}.
FT                                /FTId=VAR_019733.
FT   VARIANT      33     33       R -> Q (in PARK2; dbSNP:rs147757966).
FT                                {ECO:0000269|PubMed:12730996}.
FT                                /FTId=VAR_019734.
FT   VARIANT      37     37       P -> L (in PARK2; dbSNP:rs148990138).
FT                                {ECO:0000269|PubMed:12112109}.
FT                                /FTId=VAR_019735.
FT   VARIANT      42     42       R -> P (in PARK2 and PARK; induces a
FT                                conformational change in the PSMD4-
FT                                binding site of Ubl resulting in impaired
FT                                proteasomal binding; decreases
FT                                ubiquitination and degradation; increased
FT                                aggregation; impairs the ability to
FT                                ubiquitinate and degrade SYT11;
FT                                dbSNP:rs368134308).
FT                                {ECO:0000269|PubMed:10888878,
FT                                ECO:0000269|PubMed:11431533,
FT                                ECO:0000269|PubMed:11971093,
FT                                ECO:0000269|PubMed:15584030,
FT                                ECO:0000269|PubMed:19229105,
FT                                ECO:0000269|PubMed:20889486,
FT                                ECO:0000269|PubMed:29311685}.
FT                                /FTId=VAR_019736.
FT   VARIANT      46     46       A -> P (in PARK2).
FT                                {ECO:0000269|PubMed:12362318}.
FT                                /FTId=VAR_019737.
FT   VARIANT      56     56       V -> E (in PARK2; dbSNP:rs137853059).
FT                                {ECO:0000269|PubMed:12056932}.
FT                                /FTId=VAR_070078.
FT   VARIANT      82     82       A -> E (in PARK2; dbSNP:rs55774500).
FT                                {ECO:0000269|PubMed:11487568,
FT                                ECO:0000269|PubMed:12116199,
FT                                ECO:0000269|PubMed:12730996}.
FT                                /FTId=VAR_019738.
FT   VARIANT      92     92       A -> V (in PARK2; dbSNP:rs566229879).
FT                                /FTId=VAR_019739.
FT   VARIANT     100    100       Q -> H (in dbSNP:rs1256316516).
FT                                {ECO:0000269|PubMed:12781599}.
FT                                /FTId=VAR_019740.
FT   VARIANT     161    161       K -> N (in PARK2; severely compromises
FT                                the mitochondrial localization; fails to
FT                                stabilize BCL2; decreased binding to the
FT                                TP53 promoter; abolishes TP53
FT                                transcriptional repression;
FT                                dbSNP:rs137853057).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:19801972,
FT                                ECO:0000269|PubMed:20404107,
FT                                ECO:0000269|PubMed:20889974}.
FT                                /FTId=VAR_019741.
FT   VARIANT     167    167       S -> N (in dbSNP:rs1801474).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10511432,
FT                                ECO:0000269|PubMed:10965160,
FT                                ECO:0000269|PubMed:12629236}.
FT                                /FTId=VAR_019742.
FT   VARIANT     192    192       M -> L (in PARK2; unknown pathological
FT                                significance; dbSNP:rs9456735).
FT                                {ECO:0000269|PubMed:11971093}.
FT                                /FTId=VAR_054107.
FT   VARIANT     192    192       M -> V (in PARK2; unknown pathological
FT                                significance; dbSNP:rs9456735).
FT                                {ECO:0000269|PubMed:12629236}.
FT                                /FTId=VAR_019743.
FT   VARIANT     211    211       K -> N (in PARK2; severely compromises
FT                                the mitochondrial localization; fails to
FT                                stabilize BCL2; dbSNP:rs137853060).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:11179010,
FT                                ECO:0000269|PubMed:12114481,
FT                                ECO:0000269|PubMed:12629236,
FT                                ECO:0000269|PubMed:20404107}.
FT                                /FTId=VAR_019744.
FT   VARIANT     212    212       C -> Y (in PARK2; dbSNP:rs137853058).
FT                                {ECO:0000269|PubMed:11163284,
FT                                ECO:0000269|PubMed:12056932}.
FT                                /FTId=VAR_019746.
FT   VARIANT     240    240       T -> M (in PARK2; dbSNP:rs137853054).
FT                                {ECO:0000269|PubMed:12629236}.
FT                                /FTId=VAR_019747.
FT   VARIANT     240    240       T -> R (in PARK2; impairs the ability to
FT                                ubiquitinate SNCAIP and BCL2; loss of
FT                                UBE2L3 binding; severely compromises the
FT                                mitochondrial localization;
FT                                dbSNP:rs137853054).
FT                                {ECO:0000269|PubMed:10888878,
FT                                ECO:0000269|PubMed:11431533,
FT                                ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:20404107,
FT                                ECO:0000269|PubMed:20889974,
FT                                ECO:0000269|PubMed:9731209}.
FT                                /FTId=VAR_019748.
FT   VARIANT     253    253       C -> Y (in PARK; late onset;
FT                                dbSNP:rs747427602).
FT                                {ECO:0000269|PubMed:12730996}.
FT                                /FTId=VAR_019749.
FT   VARIANT     256    256       R -> C (in PARK2 and PARK; at
FT                                heterozygosity it is associated with late
FT                                onset Parkinson disease; impairs the
FT                                ability to ubiquitinate SNCAIP and
FT                                ZNF746; decreased binding to the TP53
FT                                promoter; abolishes TP53 transcriptional
FT                                repression; dbSNP:rs150562946).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:11971093,
FT                                ECO:0000269|PubMed:12116199,
FT                                ECO:0000269|PubMed:12730996,
FT                                ECO:0000269|PubMed:19801972}.
FT                                /FTId=VAR_019750.
FT   VARIANT     271    271       R -> S. {ECO:0000269|PubMed:12781599}.
FT                                /FTId=VAR_019751.
FT   VARIANT     275    275       R -> W (in PARK2 and PARK; at
FT                                heterozygosity it is associated with late
FT                                onset Parkinson disease; impairs the
FT                                ability to ubiquitinate SNCAIP; abolishes
FT                                p53/TP53 transcriptional repression;
FT                                impairs the ability to ubiquitinate and
FT                                degrade SYT11; dbSNP:rs34424986).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:11179010,
FT                                ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:11971093,
FT                                ECO:0000269|PubMed:12114481,
FT                                ECO:0000269|PubMed:12116199,
FT                                ECO:0000269|PubMed:12730996,
FT                                ECO:0000269|PubMed:19801972,
FT                                ECO:0000269|PubMed:21376232,
FT                                ECO:0000269|PubMed:22956510,
FT                                ECO:0000269|PubMed:29311685}.
FT                                /FTId=VAR_019752.
FT   VARIANT     280    280       D -> N (in PARK; does not affect PINK-1
FT                                dependent localization to depolarized
FT                                mitochondria; dbSNP:rs72480422).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:12730996,
FT                                ECO:0000269|PubMed:20404107}.
FT                                /FTId=VAR_019753.
FT   VARIANT     284    284       G -> R (in PARK2; dbSNP:rs751037529).
FT                                /FTId=VAR_019754.
FT   VARIANT     289    289       C -> G (in PARK2; increased aggregation;
FT                                fails to ubiquitinate SYT11; loses
FT                                ability to bind SYT11; impaired
FT                                relocalization to damaged mitochondria;
FT                                loss of function in mitophagy;
FT                                dbSNP:rs55961220).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:12925569,
FT                                ECO:0000269|PubMed:20889486}.
FT                                /FTId=VAR_019755.
FT   VARIANT     311    311       Q -> R (in a patient with Parkinson
FT                                disease; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19501131}.
FT                                /FTId=VAR_062672.
FT   VARIANT     328    328       G -> E (in PARK2; does not affect PINK-1
FT                                dependent localization to depolarized
FT                                mitochondria).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:12116199,
FT                                ECO:0000269|PubMed:20404107}.
FT                                /FTId=VAR_019756.
FT   VARIANT     334    334       R -> C (in dbSNP:rs199657839).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:27535533}.
FT                                /FTId=VAR_019757.
FT   VARIANT     339    339       A -> S. {ECO:0000269|PubMed:12781599}.
FT                                /FTId=VAR_019758.
FT   VARIANT     351    351       T -> P (in PARK2; impairs folding of IBR
FT                                domain). {ECO:0000269|PubMed:12112109,
FT                                ECO:0000269|PubMed:17360614}.
FT                                /FTId=VAR_019759.
FT   VARIANT     366    366       R -> W (in dbSNP:rs56092260).
FT                                {ECO:0000269|PubMed:10965160}.
FT                                /FTId=VAR_019760.
FT   VARIANT     371    371       A -> T (in a patient with Parkinson
FT                                disease; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19501131}.
FT                                /FTId=VAR_062673.
FT   VARIANT     380    380       V -> L (in dbSNP:rs1801582).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10965160,
FT                                ECO:0000269|PubMed:12397156,
FT                                ECO:0000269|PubMed:12730996}.
FT                                /FTId=VAR_019761.
FT   VARIANT     394    394       D -> N (in dbSNP:rs1801334).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:12397156,
FT                                ECO:0000269|PubMed:12730996}.
FT                                /FTId=VAR_019762.
FT   VARIANT     402    402       R -> C (in PARK2; dbSNP:rs55830907).
FT                                {ECO:0000269|PubMed:15584030}.
FT                                /FTId=VAR_070079.
FT   VARIANT     415    415       T -> N (in PARK2; impairs the ability to
FT                                ubiquitinate SNCAIP; does not affect
FT                                turnover of CDCRE1; impairs PINK1-
FT                                dependent localization to dysfunctional
FT                                depolarized mitochondria;
FT                                dbSNP:rs778125254).
FT                                {ECO:0000269|PubMed:10072423,
FT                                ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:15584030,
FT                                ECO:0000269|PubMed:19966284}.
FT                                /FTId=VAR_019763.
FT   VARIANT     418    418       C -> R (in PARK2; decreased binding to
FT                                the TP53 promoter; abolishes TP53
FT                                transcriptional repression; fails to
FT                                ubiquitinate SYT11 but does not loose
FT                                ability to bind SYT11).
FT                                {ECO:0000269|PubMed:12925569,
FT                                ECO:0000269|PubMed:15584030,
FT                                ECO:0000269|PubMed:19801972}.
FT                                /FTId=VAR_070080.
FT   VARIANT     430    430       G -> D (in PARK2; impairs PINK1-dependent
FT                                localization to dysfunctional depolarized
FT                                mitochondria; impaired E3 ubiquitin-
FT                                protein ligase toward ZNF746;
FT                                dbSNP:rs191486604).
FT                                {ECO:0000269|PubMed:10824074,
FT                                ECO:0000269|PubMed:11179010,
FT                                ECO:0000269|PubMed:11971093,
FT                                ECO:0000269|PubMed:12114481,
FT                                ECO:0000269|PubMed:12730996,
FT                                ECO:0000269|PubMed:19966284,
FT                                ECO:0000269|PubMed:21376232}.
FT                                /FTId=VAR_019764.
FT   VARIANT     431    431       C -> F (in PARK2; impaired E3 ubiquitin-
FT                                protein ligase toward ZNF746 and BCL2;
FT                                dbSNP:rs397514694).
FT                                {ECO:0000269|PubMed:10939576,
FT                                ECO:0000269|PubMed:20889974,
FT                                ECO:0000269|PubMed:21376232}.
FT                                /FTId=VAR_019765.
FT   VARIANT     437    437       P -> L (in PARK2; impaired E3 ubiquitin-
FT                                protein ligase toward BCL2;
FT                                dbSNP:rs149953814).
FT                                {ECO:0000269|PubMed:11971093,
FT                                ECO:0000269|PubMed:12114481,
FT                                ECO:0000269|PubMed:12629236,
FT                                ECO:0000269|PubMed:12730996,
FT                                ECO:0000269|PubMed:20889974}.
FT                                /FTId=VAR_019766.
FT   VARIANT     441    441       C -> R (in PARK2; decreased binding to
FT                                the TP53 promoter; abolishes TP53
FT                                transcriptional repression;
FT                                dbSNP:rs778305273).
FT                                {ECO:0000269|PubMed:12116199,
FT                                ECO:0000269|PubMed:19801972}.
FT                                /FTId=VAR_019767.
FT   MUTAGEN      65     65       S->E: Phosphomimetic mutant; still
FT                                requires PINK1 for activation. PRKN is
FT                                activated in presence of phosphorylated
FT                                ubiquitin. {ECO:0000269|PubMed:24660806,
FT                                ECO:0000269|PubMed:24784582}.
FT   MUTAGEN     332    332       C->S: Impairs folding of IBR domain.
FT                                {ECO:0000269|PubMed:17360614}.
FT   MUTAGEN     337    337       C->A: Impairs the ability to ubiquitinate
FT                                SNCAIP. {ECO:0000269|PubMed:11590439}.
FT   MUTAGEN     365    365       C->S: Impairs protein folding.
FT                                {ECO:0000269|PubMed:17360614}.
FT   MUTAGEN     403    403       W->A: Decreased autoinhibition and
FT                                increased E3 activity.
FT                                {ECO:0000269|PubMed:24784582}.
FT   MUTAGEN     421    421       C->A: Impairs the ability of self-
FT                                ubiquitination and to ubiquitinate
FT                                SNCAIP. {ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:18541373}.
FT   MUTAGEN     431    431       C->S: Impairs the ability to ubiquitinate
FT                                target proteins.
FT                                {ECO:0000269|PubMed:11590439,
FT                                ECO:0000269|PubMed:23727886,
FT                                ECO:0000269|PubMed:23770887}.
FT   MUTAGEN     433    433       H->N,A: Impaired activity.
FT                                {ECO:0000269|PubMed:23727886,
FT                                ECO:0000269|PubMed:23770887}.
FT   MUTAGEN     444    444       E->Q,A: Impaired activity.
FT                                {ECO:0000269|PubMed:23727886,
FT                                ECO:0000269|PubMed:23770887}.
FT   CONFLICT    223    223       S -> P (in Ref. 1; BAA25751 and 3;
FT                                AAM21458/AAM21457). {ECO:0000305}.
FT   CONFLICT    289    290       CV -> MI (in Ref. 2; AAM21461).
FT                                {ECO:0000305}.
FT   CONFLICT    339    339       A -> V (in Ref. 9; AAS88422).
FT                                {ECO:0000305}.
FT   STRAND        2     11       {ECO:0000244|PDB:5C1Z}.
FT   STRAND       13     16       {ECO:0000244|PDB:5C1Z}.
FT   STRAND       19     21       {ECO:0000244|PDB:1IYF}.
FT   HELIX        23     34       {ECO:0000244|PDB:5C1Z}.
FT   HELIX        38     40       {ECO:0000244|PDB:5C1Z}.
FT   STRAND       41     45       {ECO:0000244|PDB:5C1Z}.
FT   STRAND       48     50       {ECO:0000244|PDB:5C1Z}.
FT   TURN         52     55       {ECO:0000244|PDB:1IYF}.
FT   HELIX        56     59       {ECO:0000244|PDB:5C1Z}.
FT   TURN         62     64       {ECO:0000244|PDB:5N2W}.
FT   STRAND       66     71       {ECO:0000244|PDB:5C1Z}.
FT   HELIX       102    104       {ECO:0000244|PDB:6GLC}.
FT   STRAND      147    150       {ECO:0000244|PDB:4I1F}.
FT   TURN        152    154       {ECO:0000244|PDB:4I1F}.
FT   STRAND      156    166       {ECO:0000244|PDB:4I1F}.
FT   TURN        167    169       {ECO:0000244|PDB:4I1F}.
FT   STRAND      174    178       {ECO:0000244|PDB:4I1F}.
FT   HELIX       183    187       {ECO:0000244|PDB:4I1F}.
FT   STRAND      188    190       {ECO:0000244|PDB:6N13}.
FT   STRAND      192    196       {ECO:0000244|PDB:4I1F}.
FT   STRAND      198    200       {ECO:0000244|PDB:5N38}.
FT   STRAND      205    212       {ECO:0000244|PDB:4I1F}.
FT   STRAND      223    225       {ECO:0000244|PDB:4I1H}.
FT   TURN        239    241       {ECO:0000244|PDB:4I1F}.
FT   STRAND      246    250       {ECO:0000244|PDB:4I1F}.
FT   STRAND      257    260       {ECO:0000244|PDB:4I1F}.
FT   HELIX       261    273       {ECO:0000244|PDB:4I1F}.
FT   STRAND      278    280       {ECO:0000244|PDB:4I1F}.
FT   TURN        281    283       {ECO:0000244|PDB:4I1F}.
FT   STRAND      284    286       {ECO:0000244|PDB:4I1F}.
FT   STRAND      290    292       {ECO:0000244|PDB:6N13}.
FT   HELIX       301    307       {ECO:0000244|PDB:4I1F}.
FT   HELIX       309    326       {ECO:0000244|PDB:4I1F}.
FT   TURN        335    337       {ECO:0000244|PDB:4I1F}.
FT   STRAND      340    342       {ECO:0000244|PDB:6GLC}.
FT   STRAND      348    351       {ECO:0000244|PDB:4I1F}.
FT   STRAND      355    358       {ECO:0000244|PDB:5N38}.
FT   STRAND      363    365       {ECO:0000244|PDB:4I1F}.
FT   TURN        366    368       {ECO:0000244|PDB:4I1F}.
FT   STRAND      374    376       {ECO:0000244|PDB:6GLC}.
FT   HELIX       379    381       {ECO:0000244|PDB:4BM9}.
FT   HELIX       395    400       {ECO:0000244|PDB:4I1F}.
FT   STRAND      401    403       {ECO:0000244|PDB:5N38}.
FT   STRAND      414    417       {ECO:0000244|PDB:4I1F}.
FT   TURN        419    421       {ECO:0000244|PDB:4I1F}.
FT   STRAND      424    426       {ECO:0000244|PDB:4I1F}.
FT   STRAND      429    431       {ECO:0000244|PDB:4I1F}.
FT   STRAND      433    435       {ECO:0000244|PDB:4I1F}.
FT   TURN        439    441       {ECO:0000244|PDB:4I1F}.
FT   STRAND      444    446       {ECO:0000244|PDB:4I1F}.
FT   TURN        447    449       {ECO:0000244|PDB:4I1F}.
FT   HELIX       455    461       {ECO:0000244|PDB:4I1F}.
SQ   SEQUENCE   465 AA;  51641 MW;  9A8BB802A3FC84C3 CRC64;
     MIVFVRFNSS HGFPVEVDSD TSIFQLKEVV AKRQGVPADQ LRVIFAGKEL RNDWTVQNCD
     LDQQSIVHIV QRPWRKGQEM NATGGDDPRN AAGGCEREPQ SLTRVDLSSS VLPGDSVGLA
     VILHTDSRKD SPPAGSPAGR SIYNSFYVYC KGPCQRVQPG KLRVQCSTCR QATLTLTQGP
     SCWDDVLIPN RMSGECQSPH CPGTSAEFFF KCGAHPTSDK ETSVALHLIA TNSRNITCIT
     CTDVRSPVLV FQCNSRHVIC LDCFHLYCVT RLNDRQFVHD PQLGYSLPCV AGCPNSLIKE
     LHHFRILGEE QYNRYQQYGA EECVLQMGGV LCPRPGCGAG LLPEPDQRKV TCEGGNGLGC
     GFAFCRECKE AYHEGECSAV FEASGTTTQA YRVDERAAEQ ARWEAASKET IKKTTKPCPR
     CHVPVEKNGG CMHMKCPQPQ CRLEWCWNCG CEWNRVCMGD HWFDV
//